Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Common Equity (2019 - 2025)

Korro Bio's Common Equity history spans 7 years, with the latest figure at $51.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 67.93% year-over-year to $51.4 million, compared with a TTM value of $51.4 million through Dec 2025, down 67.93%, and an annual FY2025 reading of $51.4 million, down 67.93% over the prior year.
  • Common Equity for Q4 2025 was $51.4 million at Korro Bio, down from $99.0 million in the prior quarter.
  • The five-year high for Common Equity was $198.1 million in Q2 2024, with the low at -$153.3 million in Q3 2023.
  • Average Common Equity over 5 years is $74.8 million, with a median of $113.9 million recorded in 2022.
  • Biggest YoY gain for Common Equity was 271.57% in 2023; the steepest drop was 286.96% in 2023.
  • Tracing KRRO's Common Equity over 5 years: stood at -$42.2 million in 2021, then tumbled by 134.63% to -$99.0 million in 2022, then surged by 271.57% to $169.9 million in 2023, then dropped by 5.59% to $160.4 million in 2024, then tumbled by 67.93% to $51.4 million in 2025.
  • Per Business Quant, the three most recent readings for KRRO's Common Equity are $51.4 million (Q4 2025), $99.0 million (Q3 2025), and $115.1 million (Q2 2025).